Danna Liu, CPA, currently serves as Assistant Controller at BridgeBio Oncology Therapeutics (BBOT), a biotech company focused on cancer drug development, since January 2025. Prior to this, Danna held the position of Associate Director of Financial Reporting at FibroGen, Inc. from February 2020 to November 2024, contributing to a biopharmaceutical firm dedicated to addressing serious unmet medical needs. Danna's experience also includes managerial roles in financial reporting at Walmart between January 2016 and January 2020, as well as accounting positions at TubeMogul, Inc., International Asset Systems, and CrowdFlower Inc. Danna holds a Master of Science in Accounting from Golden Gate University and a Bachelor's degree in Business/Managerial Economics from the University of California, Davis.
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.